New hope for Tough-to-Treat kidney cancer: targeted drug trial enters final phase

NCT ID NCT03091192

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study is testing a new targeted drug called savolitinib for people with an advanced form of kidney cancer called MET-driven papillary renal cell carcinoma (PRCC). It compares savolitinib directly against sunitinib, a standard treatment, to see which is better at controlling the cancer and which has fewer side effects. The trial is for patients whose cancer has a specific genetic change (MET-driven) and who have not been treated with sunitinib or other MET-targeting drugs before.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

La Jolla, California, 92093, United States
Research Site

Atlanta, Georgia, 30322, United States
Research Site

Chicago, Illinois, 60637, United States
Research Site

Iowa City, Iowa, 52242, United States
Research Site

Boston, Massachusetts, 02215, United States
Research Site

Kansas City, Missouri, 64132, United States
Research Site

New York, New York, 10021, United States
Research Site

Nashville, Tennessee, 37203, United States
Research Site

Barretos, 14784-400, Brazil
Research Site

Curitiba, 81520-060, Brazil
Research Site

Passo Fundo, 99010-080, Brazil
Research Site

Pelotas, 096015-280, Brazil
Research Site

Porto Alegre, 90050-170, Brazil
Research Site

Porto Alegre, 90610-000, Brazil
Research Site

Porto Alegre, 91350-200, Brazil
Research Site

Rio de Janeiro, 22793-080, Brazil
Research Site

São José do Rio Preto, 15090-000, Brazil
Research Site

São Paulo, 01246-000, Brazil
Research Site

São Paulo, 01323-903, Brazil
Research Site

Bordeaux, 33000, France
Research Site

Vandœuvre-lès-Nancy, 54519, France
Research Site

Villejuif, 94805, France
Research Site

Arezzo, 52100, Italy
Research Site

Meldola, 47014, Italy
Research Site

Milan, 20133, Italy
Research Site

Modena, 41100, Italy
Research Site

Orbassano, 10043, Italy
Research Site

Pavia, 27100, Italy
Research Site

Roma, 00152, Italy
Research Site

Krasnoyarsk, 660133, Russia
Research Site

Moscow, 105077, Russia
Research Site

Moscow, 115478, Russia
Research Site

Moscow, 115522, Russia
Research Site

Moscow, RU-121356, Russia
Research Site

Murmansk, 183047, Russia
Research Site

Nizhny Novgorod, 603109, Russia
Research Site

Obninsk, 249036, Russia
Research Site

Omsk, 644013, Russia
Research Site

Saint Petersburg, 194017, Russia
Research Site

Saint Petersburg, 195271, Russia
Research Site

Saint Petersburg, 196603, Russia
Research Site

Volgograd, 400138, Russia
Research Site

Daejeon, 35015, South Korea
Research Site

Goyang-si, 10408, South Korea
Research Site

Hwasun-gun, 58128, South Korea
Research Site

Incheon, 21565, South Korea
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06273, South Korea
Research Site

Seoul, 120-752, South Korea
Research Site

Seoul, 6351, South Korea
Research Site

Dnipro, 49005, Ukraine
Research Site

Dnipro, 49102, Ukraine
Research Site

Ivano-Frankivsk, 76018, Ukraine
Research Site

Kharkiv Region, 61070, Ukraine
Research Site

Kyiv, 03022, Ukraine
Research Site

Kyiv, 03115, Ukraine
Research Site

Odesa, 65055, Ukraine
Research Site

Sumy, 40022, Ukraine

Conditions

Explore the condition pages connected to this study.

CARCINOMA CARCINOMA, RENAL CELL ENZYME INHIBITORS KIDNEY DISEASES KIDNEY NEOPLASMS NEOPLASMS BY SITE PROTEIN KINASE INHIBITORS UROLOGIC NEOPLASMS